FindTrial
Sign In

Musculoskeletal Manifestations in patients with Type 2 Diabetes Mellitus and its relation to glycemic control

Musculoskeletal Manifestations in patients with Type 2 Diabetes Mellitus and its relation to glycemic control at a tertiary care centre : A Cross-sectional Observational Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/06/088261
Enrollment
90
Registered
2025-06-04
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications

Interventions

Intervention1: Nil: Nil Intervention2: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Dr Madhavi Mathkar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The criteria for diagnosis of diabetes mellitus is according to the criteria laid down by the American Diabetes Association. Fasting blood glucose greater than 126 mg per dl Postprandial blood glucose more than 200 mg per dl. Symptoms of diabetes plus random blood glucose more than200 mg per dl Hba1c more than 6.5g percent

Exclusion criteria

Exclusion criteria: 1. Patients with a history of injury or fractures in the joint region. 2. Patients with a history of chronic liver disease. 3. Patients with a history of end-stage renal disease. 4. Patients with rheumatoid arthritis, Systemic lupus erythematosus and other connective tissue diseases.

Design outcomes

Primary

MeasureTime frame
To study the types of musculoskeletal manifestations in patients with Type 2 Diabetes Mellitus (T2DM) and their clinical profileTimepoint: 1 year—

Secondary

MeasureTime frame
1. To assess the association between glycemic control levels (measured by HbA1c) & the presence/severity of musculoskeletal manifestations.Timepoint: 1 year;2. To explore whether specific diabetic treatments (e.g. oral hypoglycemic agents, insulin therapy) & or risk factors (such as age, duration of diabetes, BMI) influence the development or progression of musculoskeletal conditions.Timepoint: 1 year—

Countries

India

Contacts

Public ContactDr Madhavi Mathkar

Dr DY Patil Medical College, Navi Mumbai

smita.patil@dypatil.edu9821027742

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026